Rodríguez-Pinilla E, Martínez-Frías M L
ECEMC (Estudio Colaborativo Español de Malformaciones Congénitas), Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Teratology. 1998 Jul;58(1):2-5. doi: 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4.
The question of whether systemic use of corticosteroids during the first trimester of pregnancy increases the risk of congenital malformations in people has still not been resolved. Here, we present the results of a case-control study on the relationship of corticosteroids during pregnancy and oral clefts in the newborn infant. Data are derived from the Spanish Collaborative Study of Congenital Malformations (ECEMC). Case subjects were 1,184 liveborn infants with nonsyndromic oral clefts. The results of the logistic regression analysis, show a relationship between exposure to corticosteroids during the first trimester of pregnancy and an increased risk of cleft lip (with or without cleft palate) in the newborn infants (OR = 6.55; CI = 1.44-29.76; P = 0.015), controlled for potential confounder factors, such as maternal smoking, maternal hyperthermia, first-degree malformed relatives with cleft lip with or without cleft palate, and maternal treatment with antiepileptics, benzodiazepines, metronidazole, or sex hormones during the first trimester of pregnancy. Thus, we believe that the use of corticosteroids during the first trimester of pregnancy, should be restricted to the following situations: for life-threatening situations, for those diseases without any other safe therapeutic alternative, or for those cases with replacement therapy.
孕期头三个月全身使用皮质类固醇激素是否会增加人类先天性畸形的风险这一问题仍未得到解决。在此,我们呈现一项关于孕期皮质类固醇激素与新生儿口腔腭裂关系的病例对照研究结果。数据源自西班牙先天性畸形协作研究(ECEMC)。病例组为1184例患有非综合征性口腔腭裂的活产婴儿。逻辑回归分析结果显示,孕期头三个月接触皮质类固醇激素与新生儿唇裂(伴或不伴腭裂)风险增加之间存在关联(比值比=6.55;可信区间=1.44 - 29.76;P = 0.015),该分析对潜在混杂因素进行了控制,如母亲吸烟、母亲体温过高、有唇裂伴或不伴腭裂的一级畸形亲属,以及母亲在孕期头三个月使用抗癫痫药、苯二氮䓬类药物、甲硝唑或性激素治疗等情况。因此,我们认为孕期头三个月使用皮质类固醇激素应限于以下情况:用于危及生命的情况、用于没有任何其他安全治疗替代方案的疾病,或用于那些需要替代治疗的病例。